Jin Yang Pharmaceutical Co., Ltd. (007370.KQ)
- Previous Close
6,260.00 - Open
6,260.00 - Bid 6,350.00 x --
- Ask 6,360.00 x --
- Day's Range
6,220.00 - 6,390.00 - 52 Week Range
4,860.00 - 8,840.00 - Volume
135,855 - Avg. Volume
107,054 - Market Cap (intraday)
72.56B - Beta (5Y Monthly) 0.44
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date --
- Forward Dividend & Yield 150.00 (2.40%)
- Ex-Dividend Date Dec 27, 2024
- 1y Target Est
--
Jin Yang Pharmaceutical Co., Ltd. engages in the pharmaceutical business in South Korea. The company offers products for anti-diabetics, antivirals, anti-hypertensives, anti-coagulants, antihistamines, antipyretics, and analgesics; digestive, respiratory, and neuropsychiatric system. It also provides drugs for genito-urinary system, anti-osteoporosis drugs, antimicrobials and antibiotics; and over the counter drugs antipyretics and analgesics. It also provides products for digestive, genito-urinary, neuropsychiatric, circulatory, and dermatological system. In addition, the company offers products for muscle relaxants, anti-hyperlipidemics, multivitamins and nutritionals, hepatics, anti-anemics, anti-obesity drugs, dental care drugs, and ophthalmic drugs. Jin Yang Pharmaceutical Co., Ltd. was founded in 1971 and is based in Seoul, South Korea.
www.jinyangpharm.com--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 007370.KQ
View MorePerformance Overview: 007370.KQ
Trailing total returns as of 5/15/2025, which may include dividends or other distributions. Benchmark is KOSPI Composite Index (^KS11) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 007370.KQ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 007370.KQ
View MoreValuation Measures
Market Cap
71.53B
Enterprise Value
149.20B
Trailing P/E
2.63
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.69
Price/Book (mrq)
0.60
Enterprise Value/Revenue
1.32
Enterprise Value/EBITDA
3.65
Financial Highlights
Profitability and Income Statement
Profit Margin
26.20%
Return on Assets (ttm)
4.21%
Return on Equity (ttm)
28.46%
Revenue (ttm)
113.33B
Net Income Avi to Common (ttm)
29.69B
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
2.01B
Total Debt/Equity (mrq)
66.47%
Levered Free Cash Flow (ttm)
-85.37B